Ann: Multiple TCF Prospectivity Identified - Eastern Cabora Bassa, page-120

First 120 Last

Share
Profile

Follow
mackeral

3,712 Posts.

259

03/09/24

17:20

Post #: 75510780
Share

Originally posted by pilko3 ↑

Probably not that necessary as he will be busy with the BOD trying to get a total buy out at between $800m and $1.2b.
Dragging the chain is just what it is and we all suffer from un foreseen delays but the mindboggling thing is go back 4 years and 3 months or so...SP was 1 cent more than today. I am guilty of impatience during this 4 year stretch...sure could have sold out at 4 time today's SP but were we being led along with promises of King Solomon's riches laying just out of reach and everything is imminent...yes we were. Not complaining as such but actually projecting forward instead of living in the NOW...a loss making monster of a stock. When she blows she blows...another several years I suppose.
Happily loving the gas to power scenario/strategy but we ain't got a flow test to bless ourselves with as yet...
What we have got is our hands on a monster basin of gas...money we haven't got in spades and we still are slightly unsure if we have gas in spades.
I am shitty at patience that is apparent yes? In the end I hold and hang on tight for the ride at 50% underwater at least...more fool me. seeing a 30 bagger within 3 years...$2,40 SP. Now where did I hear that before?
Yes SM's life and job is tough...monster salary, shite load of shares even though he didn't support the raising...the latest rort re director options is a worry though eh? If the deal was as good as they are trying to paint it why would they care about a few cents extra per option to convert? Let the SP tell the real story this is no fantasy ride watch and ride the SP.
When and if ever they hit 5 cents I will back up the truck! Ask yourself the question...what would a smart person do?
Sell, Hold or buy more?

Expand

I'm starting to buy small Parcells now at this price just so I'm in and increase the buys weekly..

IVZ Price at posting: 7.3¢ Sentiment: None Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 196 more messages in this thread...

First 120 Last

Add IVZ (ASX) to my watchlist

(20min delay)
Last 7.7¢		Change 0.000(0.00%)		Mkt cap ! $116.7M

Open	High	Low	Value	Volume
7.5¢	7.7¢	7.4¢	$74.12K	990.8K

Buyers (Bids)

No.	Vol.	Price($)
2	56930	7.4¢

Sellers (Offers)

Price($)	Vol.	No.
7.7¢	12986	1

View Market Depth

No.	Vol.	Price($)
2	56930	0.074
2	39931	0.073
3	84432	0.072
3	89050	0.071
5	396817	0.070

Price($)	Vol.	No.
0.077	12986	1
0.078	254968	4
0.080	153368	5
0.081	1000	1
0.082	72100	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

IVZ (ASX) Chart

Ann: Multiple TCF Prospectivity Identified - Eastern Cabora Bassa, page-120

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Multiple TCF Prospectivity Identified - Eastern Cabora Bassa, page-120

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News